AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01695564 — intervention group
Intervention type: DEVICE
Intervention: WATCHMAN
Description: The WATCHMAN is an expandable device deployed in the LAA via a trans-septal catheter. The implanted device has a self-expanding nitinol frame to secure it in the LAA. The fabric of the WATCHMAN device is permeable to blood.
Study NCT00363519 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Double-blind period (12 wk); placebo QD The double-blind period will be followed by a 40 wk open-label extension period where MK-0431/ONO-5435 could be titrated from 50 mg QD to 100 mg QD
Study NCT00363519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin phosphate
Description: Double-blind period (12 wk); 50 mg QD The double-blind period will be followed by a 40 wk open-label extension period where MK-0431/ONO-5435 could be titrated from 50 mg QD to 100 mg QD
Study NCT04530292 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention by a pediatric nurse at the child's home
Description: The intervention will consist of a coordinated intervention by a pediatric nurse at the child's home to support the parents in the implementation of the theoretical knowledge acquired at the hospital.~Three home visits will be set up by a nurse during the first six months of the discovery of diabetes in the child. These visits will be organized during the first, fourth and sixth months after the discovery of diabetes and last about 2 hours each time. An additional visit may be set up according to the needs of families.
Study NCT03285139 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy
Description: Cognitive Behavioral Therapy 9 weekly 2-hour group CBT sessions delivered by trained lay peers.
Study NCT02883738 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tremor
Description: evaluation of the intensity of the tremor
Study NCT04396145 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Subjective Visual Vertical
Description: All subjects will have Virtual SVV before and after the operation
Study NCT03254680 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Turmeric
Description: Twenty patients will be enrolled and treated with a stable dose of orally administered turmeric oil daily for 3 months.
Study NCT03680755 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based intervention for dental anxiety
Description: Participants will complete the experimental dental anxiety management program, which will be facilitated by a person trained in psychological treatments or by dental staff. This program consists of a series of videos which provide information about dental anxiety, educate about the details of three dental procedures which are anxiety-provoking for the participant, and teach them how to cope better with the dental experience. This program will take about 60 minutes to complete.
Study NCT01257906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLIND PHOSPHATE (1.2%) AND TRETINOIN (0.025%) TOPICAL GEL
Description: Topical Gel applied in the evening for 84 days
Study NCT01257906 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ZIANA®
Description: Topical Gel applied in the evening for 84 days
Study NCT01257906 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Control
Description: Topical Gel applied in the evening for 84 days.
Study NCT03657277 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Micropatch
Description: Each micropatch contains 50 tiny projections (800 um in length)
Study NCT02693743 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation (rTMS)
Description: A Neurostar TMS Therapy System and Neurostar XPLOR coil system (Neuronetics, Malvern, Pennsylvania) will be used to deliver stimulation.
Study NCT02693743 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation (rTMS)
Description: A Neurostar TMS Therapy System and Neurostar XPLOR coil system (Neuronetics, Malvern, Pennsylvania) will be used to deliver stimulation.
Study NCT01825213 — intervention group
Intervention type: DEVICE
Intervention: Multispectral CT of the liver
Description: Analysis of the background liver and liver lesions will be performed on Multi Spectral CT images and compared to histology.
Study NCT02878473 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deceased donor Liver Transplantation
Description: Deceased donor orthotopic liver transplantation
Study NCT02106611 — intervention group
Intervention type: OTHER
Intervention: Clinical Assessment
Description: HL treatment will be determined by review of available medical records as archived at MSKCC. Recorded variables will include: (1) RT - field, fractional and cumulative dose, and duration; (2) chemotherapy - regimen, planned interval, dose per cycle, and cumulative dosages. Patients will also be asked to complete the FACT-LYM questionnaire and the FACIT Fatigue questionnaire.
Study NCT02106611 — intervention group
Intervention type: PROCEDURE
Intervention: Stress cardiac MRI
Description: Both imaging tests will be performed within a 30 day interval, with the two modalities interpreted by dedicated study investigators blinded to the results of the other modality.
Study NCT02106611 — intervention group
Intervention type: PROCEDURE
Intervention: Stress echocardiogram
Description: Both imaging tests will be performed within a 30 day interval, with the two modalities interpreted by dedicated study investigators blinded to the results of the other modality.
Study NCT04175431 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo fluciclovine PET/CT
Study NCT04175431 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo fluciclovine PET/CT
Study NCT04175431 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymphadenectomy
Description: Undergo lymphadenectomy
Study NCT04175431 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study NCT04175431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Given PO
Study NCT04175431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO
Study NCT04175431 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo fluciclovine PET/CT
Study NCT04175431 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo fluciclovine PET/CT
Study NCT04175431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: Given PO
Study NCT04175431 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PSMA PET Scan
Description: Undergo PSMA PET scan
Study NCT04175431 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PSMA PET Scan
Description: Undergo PSMA PET scan
Study NCT03265951 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramelteon
Description: 8 mg once daily administered within 30 minutes of bedtime
Study NCT03265951 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: education brochure about sleep hygiene
Study NCT04671498 — intervention group
Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood sample
Study NCT04671498 — intervention group
Intervention type: PROCEDURE
Intervention: Droplet-BC Test
Description: Undergo Droplet-BC Test
Study NCT04671498 — intervention group
Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: Medical records are reviewed
Study NCT01360242 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MIMI procedure (two-step strategy)
Description: A second coronary angiogram is performed 24-48 hours later and the physician is free to decide on the best treatment, i.e. surgery, medical treatment, or stent implantation (drug-eluting stent if indicated for on-label patients). If stenting is required and the thrombus is still too large (greater than twice the artery width), the physician could postpone stent implantation for days or weeks.
Study NCT01360242 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Immediate Stenting (one-step strategy)
Description: The physician is encouraged to implant a stent after the thrombus aspiration (drug-eluting stent if indicated for on-label patients).
Study NCT00264745 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TASK intervention
Description: The Telephone Assessment and Skill-building Kit (TASK) is an individualized 8-week intervention program geared toward reducing depression and improving general health in stroke caregivers.
Study NCT00264745 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: Minimal intervention beyond initial hospital visit.
Study NCT02700373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDC-APB
Study NCT02700373 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01740752 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: UCAN+CBT
Description: weekly manualized couple therapy plus weekly manualized individual CBT
Study NCT01740752 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT
Description: weekly manualized higher dose of individual CBT
Study NCT02293135 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Verum Stendo session on V1 and Phantom Stendo session on V2
Description: On the firt V1 visit, the patient will receive the verum Stendo session ; then on V2 visit ((V1 + 13 days +/- 2), the patient will receive the verum Stendo session On the firt visit, V1 the patient will have a phantom Stendo session (no pressure will be applied)
Study NCT02293135 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phantom Stendo session on V1 and Verum Stendo session on V2
Description: On the firt V1 visit, the patient will have a phantom Stendo session (no pressure will be applied) ; then on V2 visit ((V1 + 13 dayx +/- 2), the patient will receive the verum Stendo session
Study NCT01972243 — intervention group
Intervention type: OTHER
Intervention: no intervention
Study NCT01680536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: maraviroc
Study NCT01387139 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: 1.0 milligrams/kilogram (mg/kg) ketamine with additional doses of 0.5 mg/kg ketamine as needed (maximum single dose based on 100 kilogram (kg) person)
Study NCT01387139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Co-administered with Propofol
Description: 0.5 mg/kg ketamine and 0.5 mg/kg propofol with additional doses of 0.25 mg/kg ketamine and 0.25 mg/kg propofol as needed (maximum single dose based on 100 kg person)
Study NCT03709355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elpida®
Description: Elpida® capsules, 20mg
Study NCT03709355 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Elpida®
Description: Elpida® capsules, 20mg
Study NCT03709355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Rifampin capsules, 150mg
Study NCT03709355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifabutin
Description: Rifabutin capsules, 150mg
Study NCT03709355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: Clarithromycin Film-coated tablets, 250mg
Study NCT03709355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Omeprazole Film-coated tablets 20mg
Study NCT03709355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin Film-coated tablets, 80mg
Study NCT03709355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel+Ethinylestradiol
Description: Levonorgestrel 150 μg + Ethinylestradiol 30 μg, Film-coated tablets
Study NCT00999258 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sirolimus
Description: The subjects assigned to the sirolimus conversion group will be initiated on sirolimus 5mg po daily at which time their tacrolimus dose will be decreased by 50%. Sirolimus levels will be checked within a week and adjusted in a linear fashion to achieve a trough goal of 12-15ng/ml in subjects within 1 year post-transplant, and 8-12 ng/ml in subjects more than 1 year post-transplant. Tacrolimus will be continued in these subjects until sirolimus target trough levels are achieved. Thereafter, tacrolimus will be discontinued indefinitely.~The subjects assigned to the tacrolimus maintenance group (control group) represent our present standard of care.
Study NCT00999258 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: sirolimus
Description: The subjects assigned to the sirolimus conversion group will be initiated on sirolimus 5mg po daily at which time their tacrolimus dose will be decreased by 50%. Sirolimus levels will be checked within a week and adjusted in a linear fashion to achieve a trough goal of 12-15ng/ml in subjects within 1 year post-transplant, and 8-12 ng/ml in subjects more than 1 year post-transplant. Tacrolimus will be continued in these subjects until sirolimus target trough levels are achieved. Thereafter, tacrolimus will be discontinued indefinitely.~The subjects assigned to the tacrolimus maintenance group (control group) represent our present standard of care.
Study NCT02352038 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low-level laser therapy
Description: The test teeth will receive LLLT using a 940 nanometer diode laser (EZLASE; BIOLASE Technology Inc., Irvine, CA, USA) with output power of 330 milliwatt. The experimental side was irradiated for 30 s in two sessions, delivering an energy density of 7 Joules per square centimeter.
Study NCT02352038 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: orthodontic treatment
Description: Orthodontic treatment will be carried out using preadjusted appliances with bonded 0.022×0.028-square inch brackets/buccal tubes and 0.014-inch NiTi archwires as the first archwires. The treatment or the major part of the treatment will be completed in 12 months.
Study NCT02352038 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: orthodontic treatment
Description: Orthodontic treatment will be carried out using preadjusted appliances with bonded 0.022×0.028-square inch brackets/buccal tubes and 0.014-inch NiTi archwires as the first archwires. The treatment or the major part of the treatment will be completed in 12 months.
Study NCT00447057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m² intravenous (iv) over 10 minutes on the first day of each 21-day cycle until disease progression (PD) or unacceptable toxicity
Study NCT00447057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 150 mg given orally (po), daily (QD), starting on the first day of the first cycle
Study NCT00447057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m² iv over 10 minutes on the first day of each 21-day cycle until PD or unacceptable toxicity
Study NCT00447057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 150 mg given po, QD, starting on the first day of the first cycle
Study NCT01791725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELND005
Study NCT01791725 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04473885 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perturbation-based balance training
Description: Participants in the experimental group will receive the balance training under perturbation on Balance SystemTM SD, including limits of stability training, maze control training, random control training. The intervention is 40 min/session, 3 sessions/week for 6 weeks.
Study NCT04202380 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Azithromycin
Description: Patients will receive Azithromycin orally 1000 mg
Study NCT04202380 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ampicillin
Description: All patients will receive Ampicillin 2gm IV every 6 hours for 2 days
Study NCT04202380 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Azithromycin
Description: Azithromycin 500 mg orally once
Study NCT04202380 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Azithromycin
Description: Azithromycin 250 mg orally daily for 4 days
Study NCT02301702 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tdap
Description: Commercially available, U.S. and Guatemala licensed, 0.5mL intramuscular injection combination tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine
Study NCT02301702 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Td
Description: The tetanus toxoid and reduced diphtheria toxoid vaccine (Td) used for this study will be the same preparation used by the National Immunization Program of Guatemala
Study NCT03833999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron 8mg
Description: ondansetron, a 5HT3 receptor antagonist used clinically in nausea and vomiting
Study NCT03833999 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: abdominal MRI
Description: serial MRIs on day 1 and day 3 of the study, at baseline and 2 hours apart 0-6 hours after meal ingestion on day 1 and 0-4 hours after the meal on day 3
Study NCT03833999 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: abdominal MRI
Description: serial MRIs on day 1 and day 3 of the study, at baseline and 2 hours apart 0-6 hours after meal ingestion on day 1 and 0-4 hours after the meal on day 3
Study NCT03833999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactulose
Description: Participants will receive 20mls lactulose twice daily for 48 hours prior to the third study day
Study NCT03833999 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lactulose
Description: Participants will receive 20mls lactulose twice daily for 48 hours prior to the third study day
Study NCT03833999 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: overcoated placebo tablet, identical to the ondansetron
Study NCT00361140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Bu IV (BusulfexR) over 3 hours on days -6, -5, -4, and -3. Day -6 and -5 doses for patients on Level 1 will be 170mg/m2. This dose is based on the dose used by DeLima (2004) adjusted proportionately to achieve an AUC of 6000uM-min. Subsequent daily doses for patients on Level 1 will be adjusted to achieve an average AUC of 6000uM-min.~Day -6 and -5 doses for patients on Level 2 will be based on the mean dose required on Level 1 to achieve target AUC then adjusted proportionally for new target AUC.~Subsequent daily doses will be adjusted to achieve target AUCs.
Study NCT00361140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 40mg/m2 IV over 1 hour on days -6, -5, -4, and -3
Study NCT02048332 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Viral specific VST Infusion
Description: VSTs will be infused into stem cell transplant recipients who have evidence of viral infection or reactivation defined as any of the below:~* Blood adenovirus PCR ≥ 1,000~* Blood CMV PCR ≥ 500~* Blood EBV PCR ≥ 9,000~* Plasma BKV PCR >1,000~* Plasma JC Virus PCR >1,000~* Evidence of invasive adenovirus infection or disease, defined as the presence of adenoviral positivity in one or more sites.~* Evidence of invasive CMV infection, eg pneumonitis, retinitis, colitis~* Evidence of invasive EBV disease/infection, EBV-associated lymphoproliferation (EBV-LPD) defined as proven EBV-LPD by biopsy or probable EBV-LPD defined as an elevated EBV DNA level in the blood associated with clinical symptoms (adenopathy or fever or masses on imaging) but without biopsy confirmation, or EBV-associated malignancies.~* Evidence of symptomatic BK virus infection, which may include symptomatic hemorrhagic cystitis, or BK nephropathy.~* Evidence of PML or other CNS infection due to JC virus.
Study NCT01724138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox
Description: Patients will start their deferasirox treatment with a dose of 20 mg/kg/day.
Study NCT03362333 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Exercises were aimed at increasing the endurance and strength of the deep neck flexor and extensor muscles and of the scapular stabilizer muscles.
Study NCT03362333 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercises were aimed at increasing the endurance and strength of the deep neck flexor and extensor muscles and of the scapular stabilizer muscles.
Study NCT03362333 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain neuroscience education
Description: Pain neuroscience education covered the neurophysiology of pain, transition from acute to chronic pain and the nervous system ability to modulate the pain experience.
Study NCT03510572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]PI-2620
Description: Imaging for evaluating the accumulation of abnormal tau protein in the brain
Study NCT01261611 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: I.M. (in the muscle) injection on day 1 of up to 5 treatment cycles.
Study NCT01261611 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin type A
Description: I.M. injection on day 1 of treatment cycle 1.
Study NCT01261611 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: I.M. injection on day 1 of treatment cycle 1.